hotspot -WSS

hotspot

author：focus 2025-09-30 11:58:46 - browse：1934

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A revolution in caring for preterm infants

Wikipedia

WSS

STAT Readout: Today's biotech news includes Sana and Amylyx

6 surprising facts about sugar

Better Therapeutics data on benefit with GLP

Medicare to cover more brain scans related to Alzheimer’s drugs

Pregnancy ages women, but effects reverse after delivery

Eight reasons why you should get an updated Covid vaccine

leisure time

hotspot

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Life sciences deals on track to hit lowest point since 2017

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Akero's treatment for NASH falls short in cirrhosis study

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

6 surprising facts about sugar

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Bring on the sabbaticals for nurses

23andMe had bad news about my health. I wish a person had delivered it

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Wikipedia

Humana CEO Bruce Broussard to step down in 2024

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Yancopoulos of Regeneron works to expand Dupixent success

STAT Readout: Today's biotech news includes Sana and Amylyx

European regulators consider appeal over Amylyx ALS drug

Wellcome Trust names Røttingen as its new CEO

hotspot

leisure time

Wikipedia

knowledge